m.Stock by Mirae AssetOpen Demat Account
m.Stock by Mirae Asset
Samrat Pharmachem Ltd logo

Samrat Pharmachem Ltd Share Price

Current price unavailable.
As on - | -
PharmaceuticalsSmall Cap

Volume Analysis

SPOT Pivot Levels

TypeClassicFibonacci
R1 --
R2--
R3--
PP- -
S1--
S2--
S3 --

Ratios

ParticularsDec 2025Sep 2025Jun 2025Mar 2025Dec 2024
ROCE-4.92-12.92-
ROE-2.22-9.91-
EPS-1.49-1.9-0.74-1.299.01

Peer Comparison

No data available
Scrip NamePriceDaily changeM CapPE Ratio1 Year Return

Corporate Action

April 7, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Samrat Pharmachem Ltd-</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1992PLC017820</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Nishant Kankaria <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: contact@samratpharmachem.in</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Rajesh Mehta <br/> Designation: CFO <br/> EmailId: rajesh@samratpharmachem.com</div> </div> <div> <br/> Date: 07/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

About Samrat Pharmachem Ltd

Equity img
Samrat Pharmachem Limited was incorporated on June 16, 1992 at Ankleshwar in Gujarat led by the Promoters, Mr. Lalit Mehta & Mr. Rajesh Mehta. Since then, it envisioned to focus on lodine Derivatives as their core products. The Company's principal activities are manufacturing and selling chemicals. Company is a producer of pharmaceutical chemicals. The intermediates produced are used in pharmaceut...
ISIN :INE103E01016

Registered Office

Plot No A2/3445,GIDC Phase IV

Contact number

+ 91-2646-220774

Registrars

Link Intime India Pvt Ltd
C-13 Pannalal Silk Mills Cmpd LBS Marg Bhandup West Mumbai - 400 078

Contact number

+ 91-022-25963838

Management

Lalit Mehta (Chairman)

Lalit Mehta (Director)

FAQs

The share price of Samrat Pharmachem Ltd on the BSE is - as on -